Medical Marijuana Inc and CannaNative LLC have entered a partnership to produce a cannabis product line and supply them to more than 560 US tribal nations.

According to the agreement, Medical Marijuana and its subsidiary HempMeds will produce Cannabidol (CBD) products for the CannaNative branded line for Native American marketplace and distribute them to tribal wellness centres, doctors, offices, pharmacies and dispensaries.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The two companies expect that the partnership will contribute to the development of hemp and cannabis-based economies.

"Advaxis Inc has announced private placement of its 2.2m common stock shares to raise gross proceeds of $30.3m."

Advaxis Inc has announced private placement of its 2.2m common stock shares to raise gross proceeds of $30.3m.

The offering is expected to be completed by 19 August and will be subscribed to by healthcare institutional specialist investors.

Tioma Therapeutics has raised $86m in a series A venture financing round. RiverVest Venture Partners LLC, Novo Ventures (US) Inc, F. Hoffmann-La Roche Ltd and S.R. One Limited co-led the round.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The company plans to invest the funds to advance the clinical trials of its lead drug candidate, an anti-CD47 immune checkpoint inhibitor, and also to develop its antibody portfolio.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact